Cargando…

The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

BACKGROUND AND PURPOSE: Magee Equations have been developed as accurate tools for predicting response and clinical outcomes in breast cancer patients treated with adjuvant systemic therapy using basic clinicopathological parameters. This study aims to evaluate the alternative application of Magee Eq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saigosoom, Napat, Sa-nguanraksa, Doonyapat, O-charoenrat, Eng, Thumrongtaradol, Thanawat, O-charoenrat, Pornchai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152538/ https://www.ncbi.nlm.nih.gov/pubmed/32308485 http://dx.doi.org/10.2147/CMAR.S237423

Ejemplares similares

A Comparison Between the Online Prediction Models CancerMath and PREDICT as Prognostic Tools in Thai Breast Cancer Patients
por: Polchai, Nuanphan, et al.
Publicado: (2020)

The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome
por: Sa-nguanraksa, Doonyapat, et al.
Publicado: (2020)

The Role of Vascular Endothelial Growth Factor A Polymorphisms in Breast Cancer
por: Sa-nguanraksa, Doonyapat, et al.
Publicado: (2012)

Gail Model Underestimates Breast Cancer Risk in Thai Population
por: Sa-Nguanraksa, Doonyapat, et al.
Publicado: (2019)

Establishment and characterization of novel highly aggressive HER2-positive and triple-negative breast cancer cell lines
por: Thongchot, Suyanee, et al.
Publicado: (2021)

Expression of androgen receptor and its regulatory molecule Lin28 in non-luminal subtype breast cancer
por: Sa-Nguanraksa, Doonyapat, et al.
Publicado: (2020)

Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells
por: Amornsupak, Kamolporn, et al.
Publicado: (2014)

Filariasis of the breast caused by Brugia pahangi: A concomitant finding with invasive ductal carcinoma
por: Thongpiya, Jerapas, et al.
Publicado: (2021)

Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer
por: Oo, Khine Kyaw, et al.
Publicado: (2021)

A German AWMF’s S2e/realist synthesis and meta-narrative snapshot of craniomaxillofacial manifestations in COVID-19 patients: Rapid living update on 1 January 2021
por: Pitak-Arnnop, Poramate, et al.
Publicado: (2022)

The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry
por: Bhargava, Rohit, et al.
Publicado: (2023)

Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
por: Sumransub, Nuttavut, et al.
Publicado: (2020)

One-Step Surface-Treatment Reagent (35% 3-O-Ethyl-l-ascorbic Acid Plus 50% Citric Acid Solution) Restores the Shear Bond Strength of Metal Brackets Bonded to Bleached Human Enamel: An In Vitro Study
por: Saeoweiang, Pichanee, et al.
Publicado: (2023)

The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer
por: Bhargava, Rohit, et al.
Publicado: (2020)

Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors
por: Suntiparpluacha, Monthira, et al.
Publicado: (2023)

Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells
por: Jirapongwattana, Niphat, et al.
Publicado: (2022)

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer
por: Chen, Xinfeng, et al.
Publicado: (2017)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

CRMAGE: CRISPR Optimized MAGE Recombineering
por: Ronda, Carlotta, et al.
Publicado: (2016)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma
por: Curioni-Fontecedro, A., et al.
Publicado: (2015)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status?
por: Harbeck, Nadia
Publicado: (2018)

Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
por: Lee, In Hee, et al.
Publicado: (2020)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Erratum to “Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma”
por: Curioni-Fontecedro, A., et al.
Publicado: (2019)

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2017)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2011)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer
por: Sevcikova, Katarina, et al.
Publicado: (2013)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
por: Arai, Roberto J., et al.
Publicado: (2018)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ml3ovhospleae303mgk1k751n8